Key Highlights

  • NanoViricides (NYSEAMERICAN:NNVC) reported a net loss of USD 5,742,936 for the quarter ended September 30, 2026, against USD 1,785,058 a year earlier.
  • Research and development spending rose to USD 4,697,186 from USD 993,066 as the Mpox and Ebola Phase II trials in the Democratic Republic of the Congo ran together.
  • Cash and cash equivalents were about USD 2.6 million, with accumulated Deficit near USD 162.8 million and a related party Credit line of USD 3 million.
  • The company began selling shares under its at-the-market program on November 11, with 3,051 shares sold at USD 1.40 through November 13.

Two Phase II Trials Lift Operating Loss to USD 5.8 Million

NanoViricides (NYSEAMERICAN:NNVC) reported a net loss of USD 5,742,936, or USD 0.23 a share, for the quarter ended September 30, 2026, compared with USD 1,785,058 in the same quarter of 2025. Operating loss reached USD 5,768,489 against USD 1,796,685. The company develops antiviral drugs built on a host mimicry nanoviricide platform and has not generated revenue, saying none is expected in the near term. Research and Development expense rose by USD 3,704,120 to USD 4,697,186, which the filing ties to the ongoing Mpox trial and the start of an Ebola trial, both in the DRC. General and administrative expense rose to USD 1,071,303 from USD 803,619 on higher investor outreach fees. Net cash used in Operating Activities was about USD 3.6 million for the quarter, and the accumulated deficit stood near USD 162.8 million.

Mpox and Ebola Programs Drive the Spending

The lead candidate, NV-387, is an oral antiviral designed to mimic the cell surface sugars that many viruses use for attachment. The Mpox Phase II trial was formally started on or about September 23, 2026, though the company says recruitment is slow because of difficult access and the need for lab confirmation. Regulators in the DRC approved the Ebola trial on or about August 4, 2026, and the company has started its first stage. It has incurred about USD 2.7 million on the Ebola trial and about USD 1.6 million on Mpox, with roughly USD 872,000 and USD 734,000 more expected to complete them. In April 2026 the FDA granted Orphan Drug designation to NV-387 for measles, and in May 2026 it added a rare pediatric disease designation. The earlier Phase I study of 72 healthy subjects reported no dropouts and no reportable adverse events, although the final study report is still being prepared for submission to regulators.

Going Concern Doubt and a New At-the-Market Program

Cash and cash equivalents were about USD 2.6 million at September 30, against liabilities of about USD 3.2 million. Management says cash plus the USD 3 million line of credit from its chief executive should cover both Phase II trials but not planned spending for 12 months, so substantial doubt exists about its ability to continue as a going concern. On November 11 the company began selling stock through an at-the-market agreement with D. Boral Capital. Through November 13 it sold 3,051 shares at an average of USD 1.40 for net proceeds of roughly USD 4,000.

Where Things Stand

NanoViricides tripled its quarterly loss as two Clinical Trials in the DRC ran together, while cash of about USD 2.6 million and a USD 3 million related party credit line leave limited room. The filing says the funds cover both trials but not a full year of operations. Next markers are patient recruitment in the Mpox and Ebola trials, further sales under the at-the-market program, and any FDA decisions on the pending orphan drug requests for Mpox and Smallpox.